Scilex Holding Company SCLX

The St. James Bank & Trust Company Ltd. ("St. James"), Omega & Corinth Group Ltd. and Marc Wade today announced that the U.S. District Court has granted their motion to compel arbitration and stay all court proceedings in California brought by Scilex Holding Company ("Scilex")..

PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies, today announced the signing of a binding term sheet with iHolding Group LLP (“iHolding”), a private investment group headquartered in Almaty, Republic of Kazakhstan. The term sheet contemplates that iHolding will purchase $100,000,000 o

Investing.com - U.S. stock index futures edged higher on Monday as investors returned from a long holiday weekend, with technology shares leading gains.

Binding Term Sheet Supports Growth PlansScilex Holding Company (NASDAQ:SCLX) shares climbed 7% on Monday after the company announced it had signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based private investment firm iHolding Group LLP. Under the proposed agreement, iHolding would acquire approximately 6.

PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced the signing of a binding term sheet with iHolding Group LLP ("iHolding"), a private investment group headquartered in Almaty, Republic of

ZTlido's market opportunities include strong sales momentum, expanding prescription share, favorable positioning as a non-opioid amid the opioid crisis, improved formulation, and increased payer access. These factors, alongside robust IP protection and international partnership potential, position ZTlido for sustained growth.Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "ZTlido Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Key Factors Drivi

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).

PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today confirmed the previously announced payment date of June 15, 2026 (the “Payment Date”) for the dividend of Semnur Pharmaceuticals, Inc. (“Semnur”) (O

PALO ALTO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the “Board”) has set June 15, 2026 as the payment date (the “Payment Date”) for the previously announced divi

PALO ALTO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the “Board”) approved a dividend of Semnur Pharmaceuticals, Inc. (“Semnur”) (OTC: SMNR) common stock held by t

Wellgistics Health (WGRX) and Datavault AI (DVLT) said Wednesday they have entered a binding term sh

Investing.com -- Datavault AI has signed over $800 million in tokenization contracts and secured $120 million in non-dilutive funding to accelerate the rollout of its quantum-ready edge computing platform, with the company revealing a surge in first-quarter revenue on Friday.

PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its indirect subsidiary, ACEA Therapeutics, Inc, an exempted company incorporated with limited liability in the Cayman Islands (“ACEA

On March 11, 2026, Scilex Holding Company ("Scilex") filed a lawsuit in the United States District Court for the Central District of California against Marc Wade, The St. James Bank & Trust Company Ltd. ("St. James"), Omega & Corinth Group Ltd. (collectively, the "Wade Defendants") and others1 in connection with a loan agreement (the "Loan Agreement") between St. James and Scilex.

Datavault AI (DVLT) said Monday it has signed a binding term sheet for a cash contribution and reven

PALO ALTO, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has filed a complaint (the “Complaint”) in the United States District Court for the Central District of California against Marc W

PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in Quantum Scan Holdings, Inc. (“Quantum Scan”), a breakthrough medical technology comp

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties.